prasterone DHEA vaginal
Selected indexed studies
- The 2022 hormone therapy position statement of The North American Menopause Society. (Menopause, 2022) [PMID:35797481]
- The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. (Menopause, 2020) [PMID:32852449]
- Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review. (Ann Intern Med, 2024) [PMID:39250810]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The 2022 hormone therapy position statement of The North American Menopause Society. (2022) pubmed
- The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. (2020) pubmed
- Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review. (2024) pubmed
- Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause: A Systematic Review. (2023) pubmed
- The genitourinary syndrome of menopause. (2021) pubmed
- State of the art in menopause: current best practice approaches from the IMS World Congress 2024, Melbourne. (2025) pubmed
- New Innovations for the Treatment of Vulvovaginal Atrophy: An Up-to-Date Review. (2022) pubmed
- Management of genitourinary syndrome of menopause in breast cancer survivors: An update. (2022) pubmed
- Diagnosis, causes, and treatment of dyspareunia in postmenopausal women. (2023) pubmed
- Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. (2016) pubmed